FTSE 100 news / Companies and sectors / AstraZeneca / 6 October 2026
AstraZeneca (AZN): news on Tuesday 6 October 2026
+6.8 strongly positive
Coverage was dominated by the opening of AstraZeneca's $1bn R&D centre in Cambridge, Massachusetts, with hiring plans. It also covered the completed $2bn Summit Therapeutics investment and the CEO saying growth beyond 2030 needs no megamerger.
What drove it
- Massachusetts R&D centre
- Summit Therapeutics investment
- CEO growth comments
The 37 stories
- +7.5 AstraZeneca to invest over $1 billion in Massachusetts, boost workforce
Over $1bn Massachusetts investment, more workforce - +7.5 ‘We’re here at the party now:’ AstraZeneca opens new Kendall hub with big hiring plans
New Kendall hub with big hiring plans - +7.5 AstraZeneca to invest over US$1bil in Massachusetts, boost workforce
Over $1bn Massachusetts investment and hiring - +7.2 AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts
Company announces new strategic R&D centre - +7.2 AstraZeneca opens $1 billion R&D center in Kendall Square
Opens $1bn R&D centre in Kendall Square - +7.2 AstraZeneca opens new Massachusetts R&D center as part of $1 billion investment
New R&D centre in $1bn investment - +7.2 AstraZeneca to Invest Over $1 Billion in Massachusetts
Over $1bn Massachusetts investment - +7.2 AstraZeneca to invest over $1B in Massachusetts ops
Over $1bn Massachusetts investment - +7.2 AstraZeneca opens $1B R&D center in Cambridge, Massachusetts By Investing.com
Opens $1bn R&D centre in Cambridge - +7.2 AstraZeneca opens $1B R&D center in Cambridge, Massachusetts
Opens $1bn R&D centre in Cambridge - +7.2 AstraZeneca $1 Billion Cambridge Investment, New Lab Tower
$1bn Cambridge investment and new lab tower - +7.0 AstraZeneca Launches Research, Development Center in US
New US R&D centre signals expansion - +7.0 Astrazeneca Announces the Opening of Its Newest Global Strategic Research and Development (R&D) Center, in Kendall Square, Cambridge, Massachusetts
Announces opening of new global R&D centre - +7.0 AstraZeneca Opens New Global R&D Center in Cambridge’s Kendall Square
Opens new global R&D centre in Kendall Square - +7.0 AstraZeneca opens R&D center in Cambridge, Massachusetts
Opens R&D centre in Cambridge - +7.0 AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
Opens new strategic R&D centre in Cambridge - +7.0 AstraZeneca Opens Global R&D Centre in Cambridge’s Kendall Square
Opens global R&D centre in Kendall Square - +6.7 AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
CEO sees Summit drug driving cancer combinations - +6.7 AstraZeneca stock opens new Massachusetts research center
Opens new Massachusetts research centre - +6.7 AstraZeneca expands oncology strategy with Summit drug collaboration and Cambridge R&D hub
Expands oncology strategy via Summit and R&D hub - +6.3 AstraZeneca Completes $2 Billion Investment in Summit Therapeutics
Completes $2bn investment in Summit for cancer drug - +6.3 AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Completes $2bn equity investment in Summit - +6.3 How AstraZeneca is using robots to conduct science at new $1 billion Cambridge research center
Robot-driven science at new $1bn research centre - +6.3 AstraZeneca invests $2B in Summit Therapeutics to advance next-gen cancer drug ivonescimab.
$2bn Summit investment for next-gen cancer drug - +6.3 AstraZeneca completes $2B equity investment in Summit Therapeutics
Completes $2bn equity investment in Summit - +5.8 AstraZeneca CEO Pascal Soriot on new Boston site: Faster, better development of new products is the hope
CEO hopes new Boston site speeds development - +5.8 AstraZeneca expands Summit collaboration
Expands Summit collaboration - +5.0 Astra Doesn’t Need a Deal for Growth Beyond 2030, CEO Says
CEO says no deal needed for growth beyond 2030 - +5.0 AstraZeneca Eyes Growth Beyond 2030 Without Megamerger
CEO confident of growth beyond 2030 without megamerger - +5.0 AstraZeneca CEO Soriot says drugmaker can grow without big acquisition
CEO says growth possible without big acquisition - +4.2 AstraZeneca considering PHL clinical ‘center of excellence’
Considering clinical centre of excellence in Philippines - +4.2 AstraZeneca to open Manila research center
Plans to open Manila research centre - +3.3 Golden Cross Formed, AstraZeneca Stock: Explained
Golden cross is a bullish technical share signal - +3.0 BofA Forecasts 'In-line' Q3, Unchanged FY26 Outlook for AstraZeneca Amid Oncology Momentum
In-line Q3 forecast, unchanged outlook, oncology momentum noted - +2.5 EcoCeres supports AstraZeneca’s journey to net zero with its first HVO application in China’s pharmaceutical sector
Supplier supports its net zero efforts in China - +2.5 Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
CEO interview, neutral to mildly positive - +1.3 International students explored career opportunities at AstraZeneca
Minor employer-brand story about student visit
AstraZeneca: every day · Pharma and healthcare on 6 October 2026 · FTSE 100 overview for the day